About 500 reports

Global Antirheumatics Pharmaceutical Market Forecast 2023 ##.

  • Anti Rheumatic
  • Pharmaceutical
  • Therapy
  • United States
  • Market Size

Disease modifying antirheumatic drugs are further sub-segmented into corticosteroids, antimalarial, methotrexate, and others.

  • Autoimmune Disease
  • Therapy
  • World
  • Market Size
  • France
  • COMPARES KEY PLAYERS IN THE RA MARKET BASED UPON THE STRENGTH OF THEIR MARKETED AND PIPELINE PORTFOLIOS.

REV PRESS., ##(##), PP. ##-##.

  • Therapy
  • Demand
  • Forecast
  • Pfizer Inc.
  • Sanofi S.A.
  • 3.4.4 TARGETED SYNTHETIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS
  • 2.7.9 BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS

Arthritis Care and Research; ##(##): ##-## SingHealth (2014).

  • Therapy
  • Market Size
  • AbbVie Inc.
  • Galapagos NV
  • Pfizer Inc.

Rheumatoid Arthritis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026 ##.

  • Arthritis
  • Therapy
  • APAC
  • World
  • Company Financials
  • DMARDS (DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS)
  • SAARDS SALES VOLUME AND MARKET SHARE

THEY ARE SAARDS(SLOW ACTING ANTI-RHEUMATIC DRUGS), TRADTIONAL CHINESE MEDICINE, BIOLOGICAL AGENTS AND ANTIBIOTICS.

  • Therapy
  • China
  • Demand
  • Trade
  • Ltd Sichuan Xichangyangtian Pharmaceutical Co.
  • DMARDS (DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS)
  • SAARDS SALES VOLUME AND MARKET SHARE

THEY ARE SAARDS(SLOW ACTING ANTI-RHEUMATIC DRUGS), TRADTIONAL CHINESE MEDICINE, BIOLOGICAL AGENTS AND ANTIBIOTICS.

  • Therapy
  • China
  • Demand
  • Bayer AG
  • Yunnan Baiyao Group Co., Ltd.

Rheumatology Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017-2025 Chapter ##.

  • Therapy
  • World
  • Market Size
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles
  • BARICITINIB - DRUG PROFILE

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Lymphoma
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • SAN-300 - Drug Profile

SAN-## acts as an inhibitor of very late antigen ## (VLA-## or integrin alpha ## beta ##).

  • Protein Therapy
  • Therapy
  • World
  • Product Initiative
  • Strykagen Corp.
  • Dermira Raises USD7.5 Million in Private Placement of Shares

The two pivotal trials, CLAREOS-## and CLAREOS-##, enrolled a total of ##, ## patients.

  • Pharmaceutical
  • Therapy
  • United States
  • Company
  • Dermira, Inc.
  • TOFACITINIB CITRATE ER - DRUG PROFILE
  • JUN 28, 2018: XELJANZ (TOFACITINIB CITRATE) RECEIVES MARKETING AUTHORIZATION IN THE EUROPEAN UNION FOR ACTIVE PSORIATIC ARTHRITIS

Patients with moderately to severely active RA who had an inadequate response to at least one disease- modifying antirheumatic drug (DMARD) received tasocitinib ## mg or ## mg monotherapy or placebo twice a day.

  • Research And Development
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.
  • DERMIRA RAISES USD7.5 MILLION IN PRIVATE PLACEMENT OF SHARES

One such project, led by Dr.

  • Autoimmune Disease
  • Pharmaceutical
  • Therapy
  • United States
  • UCB S.A.
  • COMPANION DIAGNOSTIC ASSAY - COXIBS AND NSAIDS
  • COMPANION DIAGNOSTIC ASSAY - COXIBS AND NSAIDS PRODUCT OVERVIEW

one of the world' s leading providers of company operational data and strategic analysis, providing detailed information on tens of thousands of companies globally.

  • Analgesic
  • Biomarker
  • Immunodiagnostics
  • Therapy
  • Firalis SAS

Global Market Study on Rheumatoid Arthritis Treatment: Trends Indicate the Prevalence of New Combination Treatment and Dual Inhibitors ##.

  • Arthritis
  • Therapy
  • APAC
  • World
  • Market Size
  • Biologics Market Trends And Strategies

There has been a significant advancement for the treatment of Rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs.

  • Therapy
  • United States
  • World
  • AbbVie Inc.
  • Amgen Inc.
  • 6.2 RHEUMATOID ARTHRITIS

Glucagon-like peptide-##, commonly known as GLP-##, is a hormone produced by the proglucagon gene in the L-cells of the gut.

  • Diabetes
  • Injectable Delivery
  • Therapy
  • North America
  • Amgen Inc.

##.

  • Therapy
  • World
  • Market Size
  • BARICITINIB - DRUG PROFILE
  • of once-daily baricitinib or placebo, in addition to their background therapy.

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying antirheumatic drug (cDMARD).

  • Hair Growth
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Dec 14, 2017: Pfizer Announces FDA Approval Of Xeljanz (Tofacitinib) For The Treatment Of Active Psoriatic Arthritis
  • Mar 22, 2018: Sandoz Receives Positive Recommendation for Zessly from EMA

Xeljanz may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying anti-rheumatic drug (DMARD), such as methotrexate.

  • Autoimmune Disease
  • Biosimilar
  • Monoclonal Antibody
  • Therapy
  • United States
  • FEATURED NEWS & PRESS RELEASES
  • Melanocortin Receptor 4 (MC4R) - Product Development Milestones

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ## and ## respectively.

  • Therapy
  • United States
  • World
  • Product Initiative
  • Palatin Technologies, Inc.

According to recent findings published in the Annals of the Rheumatic Diseases, disease activity and the use of biological disease-modifying anti-rheumatic drugs among patients with RA vary from country to country, due to different contributing factors, such as per capita GDP, drug affordab

  • Biosimilar
  • Therapy
  • United Kingdom
  • Company
  • Celltrion, Inc.

Plan Details ##.

  • Therapy
  • Japan
  • United States
  • Company
  • Santen Pharmaceutical Co., Ltd.
  • RABEXIMODUM - DRUG PROFILE

Tissue inhibitor of metalloproteinase ## (TIMP-##) showed statistically significant reduction; mean change of TIMP-##, -##. ## IU, P=##. ##.

  • Hospital
  • Immunotherapy
  • Pharmaceutical
  • Therapy
  • TaiwanJ Pharmaceuticals Co., Ltd.
  • GLOBAL MARKETS DIRECT REPORT COVERAGE
  • ETANERCEPT BIOSIMILAR - DRUG PROFILE

Treatment includes painkillers, NSAID and disease-modifying anti-rheumatic drugs.

  • Biosimilar
  • Therapy
  • United States
  • Company Operations
  • Product Initiative
  • RITUXIMAB BIOSIMILAR - DRUG PROFILE
  • RITUXIMAB BIOSIMILAR - DRUG PROFILE

Truxima in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor

  • Autoimmune Disease
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • ChemoCentryx, Inc.
  • TOFACITINIB CITRATE ER - DRUG PROFILE
  • SEP 08, 2017: NICE ISSUES POSITIVE RECOMMENDATION FOR XELJANZ (TOFACITINIB CITRATE) AS A NEW TREATMENT OPTION FOR ADULTS WITH SEVERE RHEUMATOID ARTHRITIS

Xeljanz may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying anti-rheumatic drug (DMARD), such as methotrexate.

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.
  • 6-month trial opted to participate in a long-term extension study.
  • FEATURED NEWS & PRESS RELEASES

The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional diseasemodifying anti-rheumatic drug (cDMARD).

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation
  • CERTOLIZUMAB PEGOL - DRUG PROFILE

Patients were randomized to receive AM- ## ##. ## mg/ mL, ##. ## mg/ mL or placebo in a ##:##:## ratio.

  • Autoimmune Disease
  • Therapy
  • United States
  • World
  • Product Initiative
  • Mar 22, 2018: Sandoz Receives Positive Recommendation for Zessly from EMA
  • ETANERCEPT BIOSIMILAR - DRUG PROFILE

Xeljanz may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying anti-rheumatic drug (DMARD), such as methotrexate.

  • Autoimmune Disease
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative